MedTrace Logo

Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

NCT05946122 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2023-07-14

No results posted yet for this study

Summary

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Conditions

  • Renal Protection

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet

oral atorvastatin for renal protection

DRUG

placebo drug

tablet resembles atorvastatin

Sponsors & Collaborators

  • Minia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2023-12-12
Completion
2023-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05946122 on ClinicalTrials.gov